{{Rsnum
|rsid=12273744
|Gene=CNTN5
|Chromosome=11
|position=99990543
|Orientation=plus
|GMAF=0.3448
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CNTN5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 48.2 | 42.0 | 9.8
| HCB | 75.9 | 22.6 | 1.5
| JPT | 81.4 | 15.0 | 3.5
| YRI | 8.8 | 46.3 | 44.9
| ASW | 21.1 | 33.3 | 45.6
| CHB | 75.9 | 22.6 | 1.5
| CHD | 73.1 | 24.1 | 2.8
| GIH | 33.7 | 48.5 | 17.8
| LWK | 15.7 | 47.2 | 37.0
| MEX | 58.6 | 34.5 | 6.9
| MKK | 19.2 | 53.8 | 26.9
| TSI | 45.5 | 37.6 | 16.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs12273744
|Name_s=
|Gene_s=CNTN5
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 89. Study population/ethnicity: 89 Yorubans. Significance metric(s): p = 0.00006. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109350
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs12273744
|overall_frequency_n=47
|overall_frequency_d=118
|overall_frequency=0.398305
|n_genomes=31
|n_genomes_annotated=0
|n_haplomes=40
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}